Liver-expressed antimicrobial peptide 1 (LEAP-1) and LEAP-2 are widespread in fish and extremely important components of the host innate immune system. In this study, full-length cDNAs of LEAP-1 and LEAP-2 were cloned and sequenced from blunt snout bream, Megalobrama amblycephala. The open reading frames (ORF) of LEAP-1 and LEAP-2 genes encode putative peptides of 94 and 92 amino acids, which possess eight and four conserved cysteine residues, respectively. The homologous identities of deduced amino acid sequences show that the LEAP-1 and LEAP-2 of blunt snout bream share considerable similarity with those of grass carp. The mRNA expressions of LEAP-1 and LEAP-2 were detectable at different early developmental stages of blunt snout bream and varied with embryonic and larval growth. LEAP-1 and LEAP-2 were expressed in a wide range of adult tissues, with the highest expression levels in the liver and midgut, respectively. Bacterial challenge experiments showed that the levels of LEAP-1 and LEAP-2 mRNA expression were up-regulated in the liver, spleen, gill and brain of juvenile blunt snout bream. These results indicate that the LEAP-1 and LEAP-2 may play important roles in early development of embryos and fry, and may contribute to the defense against the pathogenic bacterial invasion. This study will further our understanding of the function of LEAP-1 and LEAP-2 and the molecular mechanism of innate immunity in teleosts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fsi.2013.05.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibacterial activity of recombinant liver-expressed antimicrobial peptide-2 derived from olive flounder, Paralichthys olivaceus.
Fish Shellfish Immunol
November 2024
Department of Fisheries Biology, Pukyong National University, Busan, 48513, Republic of Korea. Electronic address:
Article Synopsis
- LEAP-2 is an important antimicrobial peptide found in the liver of olive flounder, playing a key role in the fish's immune response, especially during infections.
- * Researchers cloned the LEAP-2 gene and produced it in E. coli, finding that its expression increases in the liver and head kidney when fish are infected with the bacterium Edwadrsiella piscicida.
- * The purified recombinant LEAP-2 showed significant antibacterial properties against various bacteria, disrupting their membranes and enhancing effectiveness when used alongside other antibiotics, indicating its potential as a therapeutic agent against infections.
Loss of LEAP-2 alleviates obesity-induced myocardial injury by regulating macrophage polarization.
Exp Cell Res
September 2023
Pediatrics, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, PR China. Electronic address:
Article Synopsis
- Obesity is a major public health concern linked to heart problems, particularly subclinical myocardial injury, which increases heart failure risk; this study investigates mechanisms behind this issue.
- Mice were fed a high-fat diet to create an obesity model, and researchers measured various health indicators and assessed inflammation and macrophage behavior related to heart injury.
- The study found that reducing LEAP-2 levels improved heart health in obese mice by reducing inflammation and promoting a beneficial macrophage type (M2), suggesting that targeting LEAP-2 might be a strategy to mitigate obesity-related heart damage.
Comparative study on antibacterial characteristics of the multiple liver expressed antimicrobial peptides (LEAPs) in teleost fish.
Front Immunol
March 2023
State Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, Engineering Research Center of Green Development for Conventional Aquatic Biological Industry in the Yangtze River Economic Belt, Ministry of Education, College of Fisheries, Huazhong Agricultural University, Wuhan, China.
Article Synopsis
- Antimicrobial peptides, specifically liver-expressed antimicrobial peptides (LEAPs), are crucial for the innate immune defense in vertebrates, with LEAP-1 and LEAP-2 being notable types found in fish.
- The study focused on rainbow trout and grass carp, revealing that these fish have multiple LEAPs that show different expressions and antibacterial effects, particularly in their liver.
- Results indicated that LEAP-1 from rainbow trout uniquely influences iron metabolism by internalizing ferroportin, while multiple LEAP forms demonstrate varying antibacterial activities against different bacteria, enhancing immune responses in both species.
Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials.
Antibiotics (Basel)
December 2021
Summa Health, Akron, OH 44304, USA.
Lefamulin was the first systemic pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia based on two phase 3 trials (Lefamulin Evaluation Against Pneumonia [LEAP]-1 and LEAP-2). This pooled analysis evaluated lefamulin efficacy and safety in adults with community-acquired bacterial pneumonia caused by atypical pathogens (, , and ). In LEAP-1, participants received intravenous lefamulin 150 mg every 12 h for 5-7 days or moxifloxacin 400 mg every 24 h for 7 days, with optional intravenous-to-oral switch.
View Article and Find Full Text PDFPooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
J Glob Antimicrob Resist
June 2022
Nabriva Therapeutics US, Inc., Fort Washington, PA, USA.
Objectives: Lefamulin, a pleuromutilin antibiotic approved for community-acquired bacterial pneumonia (CABP), was evaluated for microbiological efficacy in a prespecified pooled analysis of LEAP 1 and 2 phase 3 clinical trial data in patients with CABP.
Methods: In LEAP 1, adults (PORT risk class III‒V) received intravenous (IV) lefamulin 150 mg every 12 h (q12h) for 5‒7 days or moxifloxacin 400 mg every 24 h (q24h) for 7 days, with optional IV-to-oral switch. In LEAP 2, adults (PORT II‒IV) received oral lefamulin 600 mg q12h for 5 days or moxifloxacin 400 mg q24h for 7 days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!